克罗恩病：英夫利昔单抗之外的未来抗肿瘤坏死因子疗法。

Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.

作者信息

Korzenik Joshua R

机构信息

Gastrointestinal Unit, Department of Internal Medicine, Massachusetts General Hospital, 55 Fruit Street Boston, MA 02114-2622, USA.

出版信息

Gastroenterol Clin North Am. 2004 Jun;33(2):285-301, ix. doi: 10.1016/j.gtc.2004.02.009.

DOI:10.1016/j.gtc.2004.02.009

PMID:15177539

Abstract

The dramatic benefit experienced by many Crohn's disease patients treated with the anti-tumor necrosis factor-alpha (TNF-alpha) antibody infliximab underscores the centrality of this cytokine in the pathogenesis of Crohn's disease and the potential use of the therapeutic strategy of blocking TNF-alpha in this disease. In the hopes of emulating and improving on the success of infliximab, numerous strategies are being devised and studied to inhibit the actions of TNF-alpha. This article focuses on those agents, other than infliximab, which target TNF-alpha to treat inflammatory bowel disease as their central mechanism of action.

摘要

许多接受抗肿瘤坏死因子-α（TNF-α）抗体英夫利昔单抗治疗的克罗恩病患者所体验到的显著疗效，突出了这种细胞因子在克罗恩病发病机制中的核心地位，以及在该疾病中采用阻断TNF-α治疗策略的潜在用途。为了模仿并改进英夫利昔单抗的成功，人们正在设计并研究多种抑制TNF-α作用的策略。本文重点关注除英夫利昔单抗之外，以靶向TNF-α作为治疗炎症性肠病核心作用机制的那些药物。